Abbott has received authorisation from the US Food and Drug Administration (FDA) for its Libre Duo 10 Day system, described as the world’s first device to monitor both glucose and ketone levels for diabetic patients.

The company plans to introduce the device in the US later this year.

The Libre Duo 10 Day is a bio-wearable designed to track glucose in real time and monitor for rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious complication for individuals with diabetes.